IL2 and Miyoshi myopathy: Further in 1998, HD IL-2 therapy was also approved for the treatment of metastatic melanoma (MM) based on a 16% ORR with 6% CRs, 10% PRs, and 5.9 months median response duration for PRs among 270 patients with MM from 8 clinical trials (14, 15).